Programmed cell death (apoptosis) safeguards tissue homeostasis, and its dysregulation is a hallmark of cancer, neurodegeneration, and immune disorders. Detecting the earliest biochemical signatures of apoptosis therefore offers a route to sharper diagnosis, real-time therapy monitoring, and data-driven drug discovery. Electrochemical biosensors are uniquely suited to this task because they translate molecular recognition events into electrical signals that are rapid, miniaturizable, and inherently compatible with point-of-care formats. Yet their clinical translation is still limited by three persistent hurdles: (i) selective recognition in protein-rich or highly variable matrices, (ii) long-term signal stability under continuous operation, and (iii) a lack of unified analytical performance standards that hampers cross-platform benchmarking. This critical review charts the most recent material, biochemical, and microelectronic innovations that are beginning to erode these barriers, and identifies emerging strategiesfrom nanostructured electrode interfaces to signal processing that could propel electrochemical apoptosis sensing from proof-of-concept prototypes to reliable bedside tools. By aligning unresolved challenges with promising technological solutions, we aim to guide interdisciplinary efforts toward next-generation diagnostics capable of real-time apoptosis surveillance in complex biological settings.
Dry eye disease (DED) is a rampant and multifactorial ocular disorder. Conventional ocular drug delivery faces significant challenges due to the complex oc
MGN-3 (Biobran), a denatured hemicellulose compound derived from rice bran, possesses potent immunomodulatory and antitumor activity; however, its clinical application is constrained by non-specific tissue distribution, rapid systemic elimination, and poor cellular uptake. To overcome these pharmacological limitations, we engineered MGN-3-loaded lipid nanoparticles (MGN-3.LNPs) formulated with bioactive cinnamon and avocado oils to optimize targeted drug delivery against solid carcinoma. Mice bearing subcutaneous Ehrlich Ascites Carcinoma (EAC) solid tumors received free MGN-3, plain lipid nanoparticles (plain LNPs), or MGN-3.LNPs three times weekly from day 8 to day 26 post-inoculation. The administration of MGN-3.LNPs achieved superior tumor volume suppression (95.00%) compared to free MGN-3 (69.00%) and plain LNPs (63.00%) (p < 0.0001). Mechanistically, MGN-3.LNPs effectively inhibited cancer cell proliferation by suppressing Ki-67 expression while promoting expression shifts that strongly suggest the engagement of mitochondrial-mediated apoptotic signaling, including upregulation of tumor protein p53, Caspase-3, Caspase-9, poly(ADP-ribose) polymerase (PARP), and cytosolic cytochrome c (Cyt c), alongside an elevated Bax/Bcl-2 ratio and reduced 8-hydroxy-2′-deoxyguanosine (8-OHdG) levels. Flow cytometric analysis confirmed that MGN-3.LNPs induced marked G0/G1 cell cycle arrest and promoted sub-G1 apoptotic cell accumulation, which was corroborated by Annexin V/propidium iodide (Annexin V/PI) staining and semiquantitative histopathological evaluation. Furthermore, MGN-3.LNPs downregulated the gene expression of proinflammatory cytokines tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) while restoring redox homeostasis in tumor tissues. Overall, lipidic nanoencapsulation significantly enhances the therapeutic efficacy of MGN-3 against solid tumors through superior nanoscale tissue penetration, prolonged retention, and synergistic lipid–drug bioactivity.
8 June 2026 in Journal of Drug Delivery Science and Technology